Department of Ophthalmology and Visual Science, Chiba University Graduate School of Medicine, Chiba, Japan.
Biomed Res Int. 2020 Aug 17;2020:3190136. doi: 10.1155/2020/3190136. eCollection 2020.
The purpose of this study was to evaluate the long-term effects of half-time photodynamic therapy (PDT) on the retinal sensitivity in eyes with chronic central serous chorioretinopathy (CSC). Twenty-two eyes of 22 patients with chronic CSC were studied. PDT was applied with full-dose verteporfin and half-time laser duration. The best-corrected visual acuity (BCVA) and retinal sensitivity in the central 2 and 10 degrees were evaluated at the baseline, and at 12 and 24 months after the half-time PDT. The retinal sensitivity was determined by Macular Integrity Assessment microperimetry (MAIA, Centervue, Padova, Italy). The results showed that the mean retinal sensitivities in the central 2 and 10 degrees were significantly improved at 12 months (25.6 ± 2.79 dB, median; 26.11 dB, 25.6 ± 2.25 dB, median; 25.65 dB, respectively; < 0.001) and at 24 months (26.3 ± 2.62 dB, median; 27.38 dB, 26.6 ± 2.21 dB, median; 27.45 dB, respectively; < 0.001) after the treatment compared to that at the baseline (19.2 ± 3.93 dB, median; 19.34 dB, 20.9 ± 2.92 dB, median; 20.9 dB, respectively). The BCVA was also significantly improved from 0.18 ± 0.19 median; 0.15 logarithm of the minimum angle of resolution (logMAR) units at the baseline to 0.07 ± 0.15 median; 0 logMAR units at 12 months ( < 0.001) and to 0.049 ± 0.16 median; -0.039 logMAR units at 24 months ( < 0.001). We conclude that half-time PDT results in a significant improvement of the mean central retinal sensitivity for at least 24 months in eyes with chronic CSC. Thus, half-time PDT is beneficial in resolving chronic CSC for a relatively long period.
本研究旨在评估半量时的光动力疗法（PDT）对慢性中心性浆液性脉络膜视网膜病变（CSC）患者视网膜敏感性的长期影响。研究共纳入 22 例（22 只眼）慢性 CSC 患者。给予全剂量维替泊芬和半量激光持续时间的 PDT。在基线、半量 PDT 后 12 个月和 24 个月评估最佳矫正视力（BCVA）和中央 2 度和 10 度的视网膜敏感性。使用黄斑完整性评估微视野计（MAIA，Centervue，帕多瓦，意大利）来评估视网膜敏感性。结果显示，治疗后 12 个月（25.6±2.79dB，中位数；26.11dB，25.6±2.25dB，中位数；25.65dB）和 24 个月（26.3±2.62dB，中位数；27.38dB，26.6±2.21dB，中位数；27.45dB）时，中央 2 度和 10 度的平均视网膜敏感性较基线时显著提高（19.2±3.93dB，中位数；19.34dB，20.9±2.92dB，中位数；20.9dB）（均<0.001）。BCVA 也从基线时的 0.18±0.19 中位数；0.15 最小分辨角对数（logMAR）单位改善至治疗后 12 个月时的 0.07±0.15 中位数；0 logMAR 单位（<0.001）和治疗后 24 个月时的 0.049±0.16 中位数；-0.039 logMAR 单位（<0.001）。我们的结论是，半量 PDT 可使慢性 CSC 患者的平均中央视网膜敏感性至少在 24 个月内显著提高。因此，半量 PDT 对慢性 CSC 的缓解作用可持续较长时间。
